Cytori Therapeutics (CYTX-5.6%) has filed an S-1 with the SEC in preparation for an offering of subscription rights to purchase units to current shareholders. Each unit will consist of one share of Series B Preferred Stock and one (or part …
A year ago, they were trading at $1.83. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CYTX at https://www.zacks.com/ap/CYTX
CNBC10d
Stock market analysts watching Cytori Therapeutics Inc (CYTX) have recently changed their ratings on the stock. The latest reports which are outstanding on Wednesday 16th of August state 0 analysts have a rating of “strong buy”, 0 …
CYTX’s SI was 1.51M shares in August as released by FINRA ... Zevenbergen Capital Investments Llc acquired 259,510 …
Cytori Therapeutics Inc (NASDAQ:CYTX) was downgraded by stock analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued on Tuesday, August 1st. Other equities research analysts have also recently …
The stock's 50 day moving average is 1.06 and its 200 day moving average is 1.32. (CYTX) stock price has gone down by -54.34% over the last 20 trading days, and its price is -79.26% below the 52-week high. They may also be used to …
Cytori Therapeutics Inc (NASDAQ: CYTX) is having an incredibly strong start to the trading session this morning, and for good reason. The company issued a PR early this morning informing investors that it has been issued key patents. Of …
Cytori Therapeutics, Inc. is a late stage cell therapy company. that engages in the developement of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. Data from …
In analysts note published on today, Maxim Group reconfirmed their Buy rating on Cytori Therapeutics (NASDAQ:CYTX)’s stock. The PT suggests a potential upside of 1,328.57 % from company’s previous stock close. NASDAQ:CYTX is …